Samih Fourali

Queen Square MS Centre, UCL Queen Square Institute Of Neurology
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Data-Driven Fatigue Trajectories in Multiple Sclerosis and Their Predictors.

Data-Driven Fatigue Trajectories in Multiple Sclerosis and Their Predictors.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: August 17, 2026

Single-centre, prospective cohort to predict optimal individualised treatment response in multiple sclerosis (POINT-MS): a cohort profile.

Single-centre, prospective cohort to predict optimal individualised treatment response in multiple sclerosis (POINT-MS): a cohort profile.

Journal: BMJ open

Published: September 25, 2025

Correction: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.

Correction: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.

Journal: Gene therapy

Published: July 12, 2024

Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.

Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.

Journal: British journal of haematology

Published: January 06, 2020

Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma.

Clinical outcomes with fixed-duration therapy (UK real-world data) compared with continuous lenalidomide and low-dose dexamethasone therapy (FIRST trial; MM-020) for transplant-ineligible patients with newly-diagnosed multiple myeloma.

Journal: Leukemia & lymphoma

Published: November 28, 2019

Correction: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.

Correction: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.

Journal: Gene therapy

Published: July 27, 2018

Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.

Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65.

Journal: Gene therapy

Published: July 15, 2016

Does left ventricular diastolic dysfunction progress through stages? Insights from a community heart failure study.

Does left ventricular diastolic dysfunction progress through stages? Insights from a community heart failure study.

Journal: International journal of cardiology

Published: February 25, 2016

Showing 1-8 of 8

Last Updated: 09/26/2026